Tesamorelin vs Hexarelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.
Also: Examorelin, HEX
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing effect among GHRPs. Also has notable cardioprotective properties independent of GH release.
Key Comparison Insights
- Tesamorelin is FDA approved, while Hexarelin remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to Hexarelin (Human Trials).
Detailed Comparison
| Attribute | Tesamorelin | Hexarelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis. | Hexarelin activates ghrelin receptors (GHSR-1a) causing potent GH release. Uniquely, it also binds to CD36 receptors in cardiac tissue, providing cardioprotective effects independent of GH. Causes significant cortisol and prolactin elevation. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | 100-200 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | Indefinite for approved indication | 4-8 weeks (desensitization occurs) |
| Best Time to Take | Before bed (fasted) | Morning and before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients. | Studies show the highest GH release among GHRPs but with desensitization over time. Cardiac research demonstrates protection against ischemia and improved heart function. Used in GH deficiency diagnosis due to reliable GH stimulation. |
Frequently Asked Questions: Tesamorelin vs Hexarelin
What is the difference between Tesamorelin and Hexarelin?
Tesamorelin is a growth hormone peptide that an fda-approved ghrh analog used to reduce excess abdominal fat in hiv-infected patients with lipodystrophy. new f8 formulation (egrifta wr) approved march 2025 allows weekly reconstitution vs daily. Hexarelin is a growth hormone peptide that a synthetic hexapeptide gh secretagogue with the strongest gh-releasing effect among ghrps. also has notable cardioprotective properties independent of gh release. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or Hexarelin?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while Hexarelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and Hexarelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and Hexarelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.